This study is for people with chronic kidney disease (CKD) and high blood pressure (HTN). It tests a new drug combination, baxdrostat and dapagliflozin, compared to a placebo (a pill with no medicine) and dapagliflozin. The study checks if these drugs help kidneys work better and reduce heart-related deaths. eGFR measures how well kidneys filter blood, and UACR checks protein in urine, both important for kidney health.

Participants start with a 4-week period taking dapagliflozin if they aren't already using this type of medication. Then, they randomly receive either the drug combination or placebo. Visits to the study site occur at 2, 4, 8, 16, 34, and 52 weeks, then every 4 months. If someone stops the study drugs early, they still take part in visits and data collection.

• Participants must be 18 years or older with specific kidney and blood pressure levels.
• Exclusion includes very high blood pressure, certain heart issues, or recent organ transplants.
• Study duration is up to 52 weeks with scheduled follow-ups.